BRCA1 and breast cancer: In the present study, we have explored the cellular responses to metallo-intercalator ruthenium(II) complexes with the Clazpy ligand, [Ru(Clazpy)2bpy]Cl2.7H2O (1) and [Ru(Clazpy)2phen]Cl2.8H2O (2) (Figure 1)[18], in selected BRCA1-defective and triple-negative breast cancer cells as well as by testing the possibility that the N-terminal BRCA1 RING domain protein was a potential biomolecular target for these ruthenium-based anticancer agents in breast cancers.